Schizophrenia
Schizophrenia is the exception to almost everything else in psychedelic medicine. Here, classic psychedelics are not a candidate treatment but a contraindication: a personal or family history of psychosis is one of the most consistent reasons people are excluded from psychedelic trials, because drugs like psilocybin and LSD can trigger or worsen psychotic symptoms. The reason schizophrenia appears so often in this research is the opposite of treatment, it has long served as a model of psychosis, first through LSD and mescaline, later and more powerfully through ketamine. There are only narrow, cautious research threads around comorbid symptoms, and a separate effort to design non-hallucinogenic drugs inspired by this biology. The honest headline is a warning, not a therapy.
How does psychedelic research approach schizophrenia? Schizophrenia is a serious condition involving altered perception and thought, and it sits in an unusual place in psychedelic research. Because classical psychedelics can produce temporary states that resemble some symptoms, a personal or family history of psychosis is generally treated as a reason to exclude people from psychedelic trials, on safety grounds. As a result, psychedelics are not studied as a treatment for schizophrenia. The condition appears in research mainly as a reason for caution and as a model for understanding how serotonin and glutamate systems shape perception. Blossom tracks the papers in this area so you can understand the safety reasoning and the science.
Data updated
Key Insights
- 1
This page carries a warning, not a treatment claim. Classic psychedelics can trigger or worsen psychosis, and a personal or family history of schizophrenia or other psychotic disorders is a standard reason to be excluded from psychedelic-assisted therapy trials.
- 2
Schizophrenia is prominent in psychedelic research because it has been used as a model of psychosis, not as a target for treatment. Historically LSD and mescaline were studied as "psychotomimetics"; today the ketamine (NMDA-receptor) model is considered a closer match to the full picture of schizophrenia.
- 3
A 2024 meta-analysis found psychedelic-induced psychosis is uncommon in trials (around 0.2 to 0.6%), but that low figure exists precisely because people at risk are screened out. It says little about the danger for someone who actually has, or is predisposed to, a psychotic disorder.
- 4
There is no evidence that psilocybin, LSD or ketamine treats schizophrenia. The only cautious therapeutic threads are narrow and unproven: closely monitored ketamine for depressive or negative symptoms in already-treated patients, and early tolerability work, none of which is a treatment for psychosis itself.
- 5
The most useful legacy of this research is indirect: understanding the serotonin and glutamate systems these drugs act on has helped inspire new, non-hallucinogenic compounds. The honest message for anyone with psychosis is to keep to proven antipsychotic care and avoid psychedelics.
By the numbers
- 9
- Trials tracked
- 205
- Papers tracked
- 1,501
- Trial participants
as of June 2026
as of June 2026
as of June 2026
What is Schizophrenia?
Schizophrenia is a serious, long-term psychiatric disorder involving "positive" symptoms (such as hallucinations and delusions), "negative" symptoms (such as social withdrawal and loss of motivation) and cognitive difficulties. It affects about 24 million people worldwide, roughly 1 in 300[1], and while it is treatable, it can be disabling and usually requires lifelong care.
Everywhere else on this site, psychedelics are discussed as possible treatments. Schizophrenia is the deliberate exception, and the difference is important enough to state plainly at the top. Classic psychedelics act on the same serotonin 5-HT2A system implicated in psychosis and can provoke or intensify psychotic symptoms, so they are not used to treat schizophrenia, and a history of psychosis (personal or in close family) is one of the most consistent exclusion criteria across the entire field of psychedelic research.
Why, then, does schizophrenia generate so many psychedelic research papers? Because it has been central to the science in the opposite way: as a model. For decades, researchers used psychedelics, and later ketamine, to recreate aspects of psychosis in order to study it. So this page is mostly about what schizophrenia has taught psychedelic neuroscience, the risks these drugs pose to people with or prone to psychosis, and the narrow, carefully hedged research threads that do exist, rather than about any treatment you could seek.
Current Treatments
The foundation of schizophrenia treatment is antipsychotic medication, which works mainly on the brain’s dopamine system and is effective for the positive symptoms of psychosis, with clozapine reserved for treatment-resistant cases. Psychological therapies, family support, and help with employment and housing matter enormously for long-term recovery. This combination genuinely helps most people manage the condition, even if it rarely makes it disappear.
The real unmet need in schizophrenia is the negative and cognitive symptoms, which respond poorly to current drugs and drive much of the long-term disability. It is tempting to imagine psychedelics, with their effects on plasticity and cognition, might help there. But that hope runs straight into the core safety problem: the very mechanism that might be interesting is the one that can inflame psychosis. New treatments for these symptoms are being pursued through dopamine-independent routes, but the credible ones are not psychedelics, and giving a classic psychedelic to someone with schizophrenia to treat negative symptoms would be a serious risk, not a therapy.
This report summarises what Blossom’s database shows about psychedelics and schizophrenia, and it is the one topic where the honest summary is mostly a caution. Schizophrenia is not a target for psychedelic treatment; it is a contraindication and, historically, a model. Classic psychedelics can trigger or worsen psychosis, a history of psychotic illness is a standard reason to be excluded from psychedelic trials, and the large research literature here is about understanding psychosis and protecting against it, not treating schizophrenia with these drugs.
A note before the evidence
This page is a research summary, not medical advice. Its most important message is a safety one: if you have schizophrenia or another psychotic disorder, or a close family history of one, classic psychedelics such as psilocybin and LSD are not a treatment and carry a real risk of triggering or worsening psychosis. Proven antipsychotic medication and psychosocial support are the established care and should not be replaced or interrupted in favour of psychedelics. If you live with psychosis and are struggling, please stay in contact with your mental-health team rather than experimenting with these substances.
A word on scope and numbers. This topic carries one of the largest paper counts on the site, which is easy to misread as a large treatment literature. It is not. The overwhelming majority of these papers use psychedelics or ketamine to model psychosis, examine the risk of drug-induced psychosis, or explore shared brain mechanisms. The number of studies testing a psychedelic as a treatment for schizophrenia is, for good safety reasons, essentially nil. Read the count as a measure of scientific entanglement, not therapeutic promise.
Schizophrenia as a model, not a target
The deep link between psychedelics and schizophrenia is historical and conceptual. When LSD and mescaline entered research in the mid-20th century, their most influential early use was as "psychotomimetics": drugs that seemed to temporarily reproduce features of psychosis, offering a way to study an otherwise inaccessible illness. This serotonergic model of psychosis shaped decades of biological psychiatry. Later, attention shifted to glutamate, and the NMDA-receptor antagonist model, using ketamine, came to be seen as a fuller reproduction of schizophrenia because it captures negative and cognitive symptoms, not just hallucination-like effects[1].
That modelling tradition is genuinely valuable, and it is most of what the literature here represents. But it has also been refined by honest scrutiny. Careful comparisons show that the perceptual disturbances of a psychedelic experience and those of the schizophrenia spectrum are not the same phenomenon[2], and accounts from people who have experienced both psychosis and psychedelics emphasise how different the two states feel[3]. So even as a model, psychedelic psychosis is an imperfect stand-in, useful for mechanism but not a literal copy of the illness.
The risk, and why trial safety figures mislead here
The central clinical fact is risk. Classic psychedelics can precipitate psychosis, particularly in people who are predisposed, which is why essentially every modern psychedelic trial screens out personal and family histories of psychotic disorders. It is worth being precise about what the safety data do and do not show. A 2024 meta-analysis found that psychedelic-induced psychosis was rare in studied populations: about 0.002% in large population samples, 0.2% in uncontrolled trials, and 0.6% in randomised controlled trials[1].
Those reassuringly small numbers come with a crucial catch: they were generated in populations from which people at high risk had already been excluded. In other words, the low incidence is partly a product of the screening, not evidence that psychedelics are safe for people with or prone to psychosis. For someone who actually has schizophrenia, the relevant question is not the screened-trial rate but the well-recognised potential for these drugs to trigger relapse, and on that the field’s caution is consistent and deliberate. The exclusion criterion is not bureaucratic timidity; it is the single clearest safety rule in psychedelic medicine.
The narrow, hedged therapeutic threads
In the interest of completeness, there are a couple of small research threads that touch treatment, and they need to be described carefully so they are not mistaken for more than they are. Because depression and negative symptoms are common and disabling in schizophrenia, a few small studies have asked whether closely monitored ketamine might help those specific comorbid symptoms in patients already stabilised on antipsychotics. A review of ketamine for depression in people with a history of psychosis concluded it can sometimes be given under supervision without clearly worsening psychotic symptoms[4], and there is early tolerability-stage interest in MDMA for negative symptoms.
None of this is a treatment for schizophrenia, and none of it changes the contraindication on classic psychedelics. These are narrow, specialist, unproven questions about managing comorbid mood and negative symptoms in people who are already in treatment, conducted with intensive monitoring precisely because the underlying drugs are risky in this population. Presenting them as evidence that "psychedelics help schizophrenia" would be a serious distortion, and it is the kind of distortion the previous version of this page made.
What this research is actually good for
If psychedelics are not treatments for schizophrenia, what is the payoff of all this research? It is understanding, and better drug design. Decades of modelling psychosis with serotonergic and glutamatergic drugs have clarified the circuits involved, and that knowledge is now feeding a search for new medicines, including non-hallucinogenic 5-HT2A agonists engineered to retain potentially useful effects while stripping out the psychedelic experience[5], and a broader move toward antipsychotics that work outside the dopamine system. The lineage runs from psychedelic neuroscience to novel, non-psychedelic medicines, which is a real and valuable contribution.
Reading this honestly
So where does schizophrenia sit? Apart from the rest of the field, and deliberately so. It is the one major condition where the honest answer is not "promising but early" but "not a treatment, and a genuine risk". The relationship between psychedelics and schizophrenia is one of modelling and caution: these drugs have helped us understand psychosis and design better medicines, and they can also cause it. For people living with schizophrenia and those who care for them, the truthful message is the simplest on this site: stay with proven antipsychotic care, treat a history of psychosis as a firm reason to avoid psychedelics, and regard any claim that psilocybin, LSD or ketamine treats schizophrenia with deep suspicion. The value of this research lies in what it teaches, not in anything it offers to take.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Schizophrenia.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Contraindicated, not a treatment. There is no evidence psilocybin treats schizophrenia, and as a 5-HT2A agonist it can trigger or worsen psychosis. A history of psychotic disorders is a standard exclusion from psilocybin trials. Its relevance here is as a historical model of psychosis, not a therapy. (The prior "Medium/Moderate" rating was unsupported and unsafe.) | None | Very Low | Low |
| LSD Contraindicated. LSD was the original "psychotomimetic", used from the 1950s to model psychosis, and carries the same risk of provoking or worsening psychotic symptoms. No therapeutic role in schizophrenia; its place in this literature is historical and mechanistic. | None | Very Low | Low |
| Ketamine Not a treatment for schizophrenia, and the field’s main pharmacological MODEL of it: as an NMDA-receptor antagonist, ketamine reproduces positive, negative and cognitive features of psychosis. A narrow, closely monitored research thread tests it for comorbid depressive/negative symptoms in already-treated patients, but that is not a treatment for psychosis. The prior "High/Large, substantial evidence" rating was wrong and dangerous. | None | Very Low | Low |
Psilocybin and Schizophrenia
Psilocybin has no role in treating schizophrenia, and the most useful thing this section can do is say why clearly. As a serotonin 5-HT2A agonist, psilocybin acts on a system closely tied to psychosis, and it can precipitate or worsen psychotic symptoms in people who are vulnerable. That is why a personal or family history of psychotic disorders is one of the most consistent exclusion criteria in psilocybin trials[1], and why the reassuring safety record of those trials cannot be read across to people with schizophrenia.
The numbers make the point. A 2024 meta-analysis found psychedelic-induced psychosis occurred in roughly 0.2 to 0.6% of trial participants, and far less in the general population[1], which sounds low until you remember those trials deliberately excluded anyone at elevated risk. For someone who already has a psychotic disorder, the relevant risk is not that small screened figure but the well-documented potential to trigger a relapse. Psilocybin belongs on this page as a contraindication and a research tool, not a treatment.
LSD and Schizophrenia
LSD’s connection to schizophrenia is largely historical, and it is the origin of this whole strand of research. In the 1950s and 1960s, before psychedelics were treatments for anything, LSD and mescaline were studied as "psychotomimetics", drugs thought to temporarily reproduce psychosis so that it could be observed and understood. That model shaped early biological psychiatry and is why the two topics have been entangled ever since.
Modern work has both refined and questioned that model. Detailed comparisons find that the hallucinations and altered perception of a psychedelic experience differ in important ways from those of the schizophrenia spectrum[1], and people with lived experience of both report that a drug experience and an illness are not the same thing[2]. The practical conclusion is unchanged: LSD can worsen psychosis, has no therapeutic role in schizophrenia, and is contraindicated for people with the condition.
Ketamine and Schizophrenia
Ketamine is the most important compound to get right here, because the previous version of this page badly misrepresented it. Ketamine is not a proven treatment for schizophrenia. On the contrary, it is the field’s leading pharmacological model of the disorder: as an NMDA-receptor antagonist, a single dose can reproduce not just hallucination-like effects but the negative and cognitive symptoms that other models miss, which is exactly why researchers use it to study schizophrenia in healthy volunteers.
There is one genuinely cautious therapeutic thread, and it must be described precisely. Because depression is common in schizophrenia, a few small studies have asked whether carefully monitored ketamine might help depressive or negative symptoms in patients who are already stabilised on antipsychotics, and a review of ketamine for depression in people with a history of psychosis found it can sometimes be used without clearly worsening psychotic symptoms, under close supervision[1]. That is a narrow, unproven, specialist question about comorbid mood symptoms, not evidence that ketamine treats schizophrenia, and it does not change the headline: ketamine’s primary relationship to schizophrenia is as a model of it.
Clinical Outlook
The honest near-term outlook is that psychedelics will not become treatments for schizophrenia, and that the most important clinical task is the opposite: keeping the contraindication firm as psychedelic therapy expands. As more clinics offer psilocybin and related treatments for depression and other conditions, careful screening for personal and family history of psychosis becomes a frontline safety issue, and services need clear plans for the rare cases of psychedelic-induced psychosis, whose management is only now being systematically reviewed[1].
Where this research genuinely points forward is indirect. Decades of using psychedelics and ketamine to model psychosis have deepened understanding of the serotonin and glutamate systems, and that understanding is helping inspire a new generation of compounds, including non-hallucinogenic 5-HT2A agonists designed to keep useful effects while removing the psychedelic (and psychosis-like) experience[2]. The realistic future for schizophrenia is better, dopamine-independent and circuit-informed medicines that owe an intellectual debt to psychedelic neuroscience, not psychedelic treatment itself.
Industrial Landscape
Schizophrenia sits at an unusual angle to the commercial psychedelic field. There is no company developing psilocybin or LSD to treat schizophrenia, because it would be both unsafe and uninvestable; instead, the relevant industry activity is in novel antipsychotics that draw on the neuroscience this research helped build, and in the broader effort to treat the negative and cognitive symptoms that remain so poorly served. Academic researchers, meanwhile, continue to use these drugs as models to understand psychosis.
For an honest broker, schizophrenia is the clearest test of the field’s integrity. The same enthusiasm that surrounds psychedelics for depression can blur into careless claims that they might help any condition, and this is precisely where that drift becomes dangerous. The responsible position is unambiguous: hold the line that psychedelics are contraindicated in psychosis, treat the strong screening of psychedelic-therapy candidates as non-negotiable, and value this research for what it actually offers schizophrenia, scientific understanding and safer drug design, rather than letting a treatment narrative form where there is no treatment.
Quick Indicators
Organisations
Search →University of Arizona
Although the University of Arizona may not have a dedicated psychedelic research group, one of the first modern clinical trials investigating the use of psychedelics to treat a mental disorder was conducted at the University. In 2006, Dr Francisco Moreno led the first FDA-approved study in 25 years using psychedelics at UA. The study examined the use of psilocybin to treat symptoms of obsessive-compulsive disorder (OCD). Since then, researchers within the Department of Psychiatry at UA have maintained their interest in the field. Dr Moreno, along with Dr Brian Bayze and their research group, is continuing to conduct research into this particular area of psychedelic science at UA ever since the 2006 trial. There is a trial underway at UA exploring the effects of psilocybin on OCD.
National Institutes of Health (NIH)
U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.
UMC Utrecht
The University Medical Center Utrecht is a major academic hospital affiliated with Utrecht University in the Netherlands. One of the largest hospitals in the Netherlands, UMC Utrecht integrates top-level patient care, medical education, and clinical research across specialties including psychiatry, neurology, oncology, and cardiovascular medicine.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Devon Stoliker
Research Fellow / PhD Student at Monash University’s Turner Institute for Brain and Mental Health
Devon Stoliker is notable for mechanistic psychedelic neuroscience research using dynamic causal modeling and fMRI to study ego dissolution, connectivity, and context-dependent effects of psilocybin and LSD.
Gary Egan
Distinguished Professor and Foundation Director of Monash Biomedical Imaging
He is a leading neuroimaging researcher whose work has helped elucidate the brain mechanisms of psychedelics, including psilocybin- and LSD-related changes in connectivity, ego dissolution, and visual imagery.
Connected Evidence
The latest clinical data and verified academic findings associated with Schizophrenia.